Cytophage Technologies Statistics

Total Valuation

TSXV:CYTO has a market cap or net worth of CAD 2.03 million. The enterprise value is 2.85 million.

Market Cap	2.03M
Enterprise Value	2.85M

Important Dates

The last earnings date was Friday, May 15, 2026.

Earnings Date	May 15, 2026
Ex-Dividend Date	n/a

Share Statistics

TSXV:CYTO has 67.69 million shares outstanding. The number of shares has increased by 11.80% in one year.

Current Share Class	67.69M
Shares Outstanding	67.69M
Shares Change (YoY)	+11.80%
Shares Change (QoQ)	+5.19%
Owned by Insiders (%)	3.50%
Owned by Institutions (%)	1.28%
Float	64.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	1.28
P/TBV Ratio	1.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.69
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.83

Financial Position

The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.83.

Current Ratio	1.33
Quick Ratio	1.17
Debt / Equity	0.83
Debt / EBITDA	n/a
Debt / FCF	-0.38
Interest Coverage	-45.80

Financial Efficiency

Return on equity (ROE) is -182.80% and return on invested capital (ROIC) is -71.55%.

Return on Equity (ROE)	-182.80%
Return on Assets (ROA)	-63.84%
Return on Invested Capital (ROIC)	-71.55%
Return on Capital Employed (ROCE)	-158.43%
Weighted Average Cost of Capital (WACC)	4.75%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -89.09% in the last 52 weeks. The beta is 0.00, so TSXV:CYTO's price volatility has been lower than the market average.

Beta (5Y)	0.00
52-Week Price Change	-89.09%
50-Day Moving Average	0.06
200-Day Moving Average	0.17
Relative Strength Index (RSI)	43.45
Average Volume (20 Days)	177,931

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.22M
Pretax Income	-4.13M
Net Income	-4.13M
EBITDA	-3.55M
EBIT	-4.22M
Earnings Per Share (EPS)	-0.07

Full Income Statement

Balance Sheet

The company has 500,609 in cash and 1.32 million in debt, with a net cash position of -822,514 or -0.01 per share.

Cash & Cash Equivalents	500,609
Total Debt	1.32M
Net Cash	-822,514
Net Cash Per Share	-0.01
Equity (Book Value)	1.59M
Book Value Per Share	0.02
Working Capital	219,690

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.43 million and capital expenditures -12,385, giving a free cash flow of -3.44 million.

Operating Cash Flow	-3.43M
Capital Expenditures	-12,385
Depreciation & Amortization	678,745
Net Borrowing	-215,026
Free Cash Flow	-3.44M
FCF Per Share	-0.05

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TSXV:CYTO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.80%
Shareholder Yield	-11.80%
Earnings Yield	-203.43%
FCF Yield	-169.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 9, 2024. It was a reverse split with a ratio of 0.2412662.

Last Split Date	Feb 9, 2024
Split Type	Reverse
Split Ratio	0.2412662

Scores

Altman Z-Score	n/a
Piotroski F-Score	1